Aki Morikawa

1.3k total citations · 1 hit paper
49 papers, 794 citations indexed

About

Aki Morikawa is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, Aki Morikawa has authored 49 papers receiving a total of 794 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 29 papers in Oncology and 11 papers in Genetics. Recurrent topics in Aki Morikawa's work include Brain Metastases and Treatment (28 papers), Glioma Diagnosis and Treatment (11 papers) and Cancer Treatment and Pharmacology (11 papers). Aki Morikawa is often cited by papers focused on Brain Metastases and Treatment (28 papers), Glioma Diagnosis and Treatment (11 papers) and Cancer Treatment and Pharmacology (11 papers). Aki Morikawa collaborates with scholars based in United States, United Kingdom and Japan. Aki Morikawa's co-authors include Andrew D. Seidman, Sujata Patil, N. Lynn Henry, Elena Pentsova, Ian E. Krop, Nancy U. Lin, Sarat Chandarlapaty, Helen R. Thorsheim, David M. Peereboom and Paul R. Lockman and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Aki Morikawa

46 papers receiving 784 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update

2022 116 citations Sharon H. Giordano, Maria Alice Franzoi et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aki Morikawa United States	15	498	462	202	141	120	49	794
Chiara Biagioni Italy	17	614 1.2×	509 1.1×	155 0.8×	363 2.6×	262 2.2×	45	960
Anantbhushan Ranade India	11	557 1.1×	286 0.6×	84 0.4×	121 0.9×	228 1.9×	32	795
Neelima Vidula United States	16	476 1.0×	321 0.7×	60 0.3×	196 1.4×	177 1.5×	67	719
Emanuela Risi Italy	15	411 0.8×	378 0.8×	86 0.4×	178 1.3×	238 2.0×	39	673
Amelia Zelnak United States	15	530 1.1×	388 0.8×	146 0.7×	310 2.2×	318 2.6×	45	1.0k
Pietro De Placido Italy	13	488 1.0×	396 0.9×	77 0.4×	225 1.6×	245 2.0×	53	816
Andrea Gombos Belgium	15	529 1.1×	239 0.5×	61 0.3×	210 1.5×	303 2.5×	40	805
Xiaodong Su China	16	207 0.4×	288 0.6×	99 0.5×	212 1.5×	311 2.6×	38	752
Graham H.P. Richmond United Kingdom	5	473 0.9×	321 0.7×	65 0.3×	175 1.2×	492 4.1×	6	947
Natsuko Nomura United States	13	168 0.3×	157 0.3×	117 0.6×	202 1.4×	275 2.3×	29	676

Countries citing papers authored by Aki Morikawa

Since Specialization

Citations

This map shows the geographic impact of Aki Morikawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aki Morikawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aki Morikawa more than expected).

Fields of papers citing papers by Aki Morikawa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aki Morikawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aki Morikawa. The network helps show where Aki Morikawa may publish in the future.

Co-authorship network of co-authors of Aki Morikawa

This figure shows the co-authorship network connecting the top 25 collaborators of Aki Morikawa. A scholar is included among the top collaborators of Aki Morikawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aki Morikawa. Aki Morikawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

O’Brien, Barbara, Rashmi K. Murthy, Donald A. Berry, et al.. (2024). Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results.. Journal of Clinical Oncology. 42(16_suppl). 2018–2018. 4 indexed citations

Hamilton, Erika, Timothy Pluard, Judy S. Wang, et al.. (2024). H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).. Journal of Clinical Oncology. 42(16_suppl). 1015–1015. 4 indexed citations

Bao, Liwei, Cheng Xu, Zhaoping Qin, et al.. (2024). Targeting fatty acid synthase in preclinical models of TNBC brain metastases synergizes with SN-38 and impairs invasion. npj Breast Cancer. 10(1). 43–43. 17 indexed citations

Morikawa, Aki, Aaron M. Udager, Liwei Bao, et al.. (2023). Personalized medicine for brain metastases (BrMets) through patient-derived organoid (PDO) drug testing.. JCO Global Oncology. 9(Supplement_1). 11–11.

Yates, Joel A., Megan Altemus, Liwei Bao, et al.. (2023). Blood–Brain Barrier Remodeling in an Organ‐on‐a‐Chip Device Showing Dkk1 to be a Regulator of Early Metastasis. SHILAP Revista de lepidopterología. 3(4). 9 indexed citations

Morikawa, Aki, Peter Ulintz, Xu Cheng, et al.. (2023). Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment. Cancer Research Communications. 3(6). 1093–1103. 2 indexed citations

Giordano, Sharon H., Maria Alice Franzoi, Sarah Temin, et al.. (2022). Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology. 40(23). 2612–2635. 116 indexed citations breakdown →

Ramakrishna, Naren, Carey K. Anders, Nancy U. Lin, et al.. (2022). Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update. Journal of Clinical Oncology. 40(23). 2636–2655. 41 indexed citations

Nelson, David R., Jacqueline Brown, Aki Morikawa, & Michael Method. (2022). Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics. PLoS ONE. 17(2). e0264637–e0264637. 29 indexed citations

10.

Kim, Michelle M., Hemant Parmar, Matthew J. Schipper, et al.. (2020). BRAINSTORM: A Multi-Institutional Phase 1/2 Study of RRx-001 in Combination With Whole Brain Radiation Therapy for Patients With Brain Metastases. International Journal of Radiation Oncology*Biology*Physics. 107(3). 478–486. 10 indexed citations

11.

Morikawa, Aki, Elisa de Stanchina, Elena Pentsova, et al.. (2019). Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases. Clinical Cancer Research. 25(13). 3784–3792. 35 indexed citations

12.

Ulintz, Peter, Liwei Bao, John P. Lloyd, et al.. (2019). Molecular determinants of drug response in TNBC cell lines. Breast Cancer Research and Treatment. 179(2). 337–347. 8 indexed citations

13.

Morikawa, Aki, Rui Wang, Sujata Patil, et al.. (2017). Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection. Clinical Breast Cancer. 18(5). 353–361. 11 indexed citations

14.

Morikawa, Aki, et al.. (2016). Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis. Clinical Breast Cancer. 17(1). 23–28. 78 indexed citations

15.

Morikawa, Aki & N. Lynn Henry. (2015). Palbociclib for the Treatment of Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer. Clinical Cancer Research. 21(16). 3591–3596. 32 indexed citations

16.

Morikawa, Aki, et al.. (2015). Characteristics and outcomes of breast cancer patients with leptomeningeal metastasis at Memorial Sloan Kettering Cancer Center (MSKCC).. Journal of Clinical Oncology. 33(15_suppl). 2026–2026.

17.

Yang, Jonathan T., Jung Hun Oh, Michael R. Folkert, et al.. (2014). Outcomes and Prognostic Factors in Women With 1 to 3 Breast Cancer Brain Metastases Treated With Definitive Stereotactic Radiosurgery. International Journal of Radiation Oncology*Biology*Physics. 90(3). 518–525. 25 indexed citations

18.

Morikawa, Aki, Vijay Varma, Theresa Gillespie, et al.. (2007). Counting alleles in single lesions of prostate tumors from ethnically diverse patients. The Prostate. 68(3). 231–240. 2 indexed citations

19.

Zhong, Diansheng, Aki Morikawa, Lizheng Guo, et al.. (2006). Homozygous deletion of SMAD4 in breast cancer cell lines and invasive ductal carcinomas. Cancer Biology & Therapy. 5(6). 601–607. 24 indexed citations

20.

Hasegawa, Setsuo, Hisakuni Sekino, Osamu Matsuoka, et al.. (2003). Bioequivalence of Rebamipide Granules and Tablets in Healthy Adult Male Volunteers. Clinical Drug Investigation. 23(12). 771–779. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact